Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma

Abdel‐Rahman, Omar; El-Sayed, Zeinab

doi:10.1002/14651858.cd011313.pub3

Cited by 9 publications

(7 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our systematic review for the overall survival are aligned with those of five systematic reviews showing no effect with the use of Y90-TARE [8,[31][32][33][34], but are in contradiction with three other systematic reviews [9,35,36]. Our work is however more exhaustive and not limited to one specific comparator in the context of absence of a unique standard of care.…”

Section: Discussionsupporting

confidence: 59%

“…Previous systematic reviews suggesting a survival benefit with the use of Y90-TARE [9,35,36] had major limitations in their design including the consideration of non-randomised controlled studies. Differing from other systematic reviews [8,[31][32][33], our work examined both progression-free survival and time to progression, which are outcomes used as primary endpoints in some randomized controlled trials in HCC. Our results suggesting that the use of glass microsphere Y90-TARE may possibly be associated with longer time to progression as compared to standard of care treatment differ from prior meta-analyses [8,9,[31][32][33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

“…Differing from other systematic reviews [8,[31][32][33], our work examined both progression-free survival and time to progression, which are outcomes used as primary endpoints in some randomized controlled trials in HCC. Our results suggesting that the use of glass microsphere Y90-TARE may possibly be associated with longer time to progression as compared to standard of care treatment differ from prior meta-analyses [8,9,[31][32][33][34][35][36]. Previous studies comparing the resin and glass microsphere to deliver the treatment showed conflicting results [37,38].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background Recently, the use of Yttrium-90 transarterial radioembolization in non-surgical hepatocellular carcinoma was suggested but the evidence supporting its use is unclear. Methods We searched Medline, Embase, Web of Science and Cochrane CENTRAL from inception up to April 14, 2020 for randomized controlled trials comparing Y90-TARE to standard of care in non-surgical HCC patients. Our primary outcome was overall survival (OS). Our secondary outcomes were progression-free survival, time to progression, disease control rate, grade ≥3 adverse events and rates of gastro-intestinal ulcers. Hazard ratios (HR) and risk ratios (RR) with random-effects model were used for our analyses. The risk of bias of the included studies was assessed using Cochrane’s RoB 2 tool. Results Of 1,604 citations identified, eight studies (1,439 patients) were included in our analysis. No improvement in overall survival were noted when Yttrium-90 transarterial radioembolization was compared to standard treatments (HR 0.99 [95% CI 0.81–1.21], 6 studies, I2 = 77.6%). However, Yttrium-90 transarterial radioembolization was associated with fewer grade ≥3 adverse events (RR 0.64 [95% CI 0.45–0.92], 7 studies, I2 = 66%). No difference was observed on other secondary outcomes. Discussion In non-surgical HCC patients, Yttrium-90 transarterial radioembolization was not associated with significant effect on survival, progression-free survival, time to progression, disease control rate and the incidence of gastro-intestinal ulcers but was however associated with significantly lower rates of grade ≥3 adverse events. Further randomized controlled trials are warranted to better delineate optimal treatment.

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…RCL1, an RNA 3′-terminal phosphate cyclase-like protein, is ubiquitously expressed in various tissues and has been shown to participate in the ribosome biogenesis, rRNA processing, and Gene Expression pathway (https:// www.genecards.org/cgi-bin/carddisp.pl?gene�RCL1) [6,[16][17][18]. Defects in the ribosomal biogenesis can result in cirrhosis and P53 activation and are associated with tumorigenesis [19,20].…”

Section: Discussionmentioning

confidence: 99%

Identifying Prognostic Significance of RCL1 and Four-Gene Signature as Novel Potential Biomarkers in HCC Patients

Liu

Zhang

Chen

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) is a highly malignant disease, and it is characterized by rapid progression and low five-year survival rate. At present, there are no effective methods for monitoring the treatment and prognosis of HCC. Methods. The transcriptome and gene expression profiles of HCC were obtained from the Cancer Genome Atlas (TCGA) program, International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus (GEO) databases. The random forest method was applied to construct a four-gene prognostic model based on RNA terminal phosphate cyclase like 1 (RCL1) expression. The Kaplan-Meier method was performed to evaluate the prognostic value of RCL1, long noncoding RNAs (AC079061, AL354872, and LINC01093), and four-gene signature (SPP1, MYBL2, TRNP1, and FTCD). We examined the relationship between RCL1 expression and immune cells infiltration, tumor mutation burden (TMB), and microsatellite instability (MSI). Results. The results of multiple databases indicated that the aberrant expression of RCL1 was associated with clinical outcome, immune cells infiltration, TMB, and MSI in HCC patients. Meanwhile, we found that long noncoding RNAs (AC079061, AL354872, and LINC01093) and RCL1 were significantly coexpressed in HCC patients. We also confirmed that the four-gene signature was an independent prognostic factor for HCC patients. Ferroptosis potential index, immune checkpoint molecules, and clinical feature were found to have obvious correlations with risk score. The area under the receiver operating characteristic curve values for the model were 0.7–0.8 in the training set and the validation set, suggesting high robustness of the four-gene signature. We then built a nomogram for facilitating the use in clinical practice. Conclusion. Our study demonstrated that RCL1 and a novel four-gene signature can be used as prognostic biomarkers for predicting clinical outcome in HCC patients; and this model may assist in individualized treatment monitoring of HCC patients in clinical practice.

show abstract

“…90 The survival benefit is not reported to be very different from TACE ranging from 14 to 16.9 months, but TARE demonstrated reduced toxicity and longer time to progression of disease (13.3 vs 8.4 months). 91 , 92 …”

Section: Ethodsmentioning

confidence: 99%

Updates on the Diagnosis and Management of Hepatocellular Carcinoma

Raees

Kamran²,

Özkan

et al. 2021

Euroasian Journal of Hepato-Gastroenterology

View full text Add to dashboard Cite

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma

Abstract: Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (Review)

Cited by 9 publications

References 84 publications

Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis

Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis

Identifying Prognostic Significance of RCL1 and Four-Gene Signature as Novel Potential Biomarkers in HCC Patients

Updates on the Diagnosis and Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About